The synergistic and enhancive effects of IL-6 and M-CSF to expand and differentiate functional dendritic cells from human monocytes under serum-free condition

Journal of Biological Engineering

Research

Tsung-Yu Tseng¹  Chao-Ling Yao¹ 

[1] Department of Chemical Engineering, National Cheng Kung University, No. 1, University Road, 70101, Tainan, Taiwan;

关键词: Dendritic cell;    Serum-free;    IL-6;    M-CSF;    Immunotherapy;   

DOI  :  10.1186/s13036-023-00325-z

 received in 2022-11-11, accepted in 2023-01-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundDendritic cells (DCs) are differentiated from monocytes, and have a strong ability to perform phagocytosis, present antigens and activate T cell immune response. Therefore, DCs are one of the key factors in fighting cancer in immunotherapy, and it is an important issue to develop a serum-free system for DC differentiation and expansion in vitro for clinical application.ResultsIn this study, IL-6 and M-CSF were determined and a concentration combination of cytokines was optimized to develop an optimal DC serum-free differentiation medium (SF-DC Optimal) that can effectively differentiate CD14+ monocytes into CD40+CD209+ DCs. After differentiation, the morphology, growth kinetics, surface antigen expression, phagocytosis ability, cytokine secretion, mixed lymphocyte reaction and stimulation for maturation of the differentiated DCs were checked and confirmed. Importantly, this research is the first report finding that the addition an extra low concentration of IL-6 and M-CSF exhibited a synergistic effect with GM-CSF and IL-4 to generate higher numbers and more fully functional DCs than the addition of GM-CSF and IL-4 only under serum-free condition.ConclusionA large number of functional DCs can be generated by using SF-DC Optimal medium and provide an alternative source of DCs for related basic research and clinical applications.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

41116_2022_35_Article_IEq532.gif

41116_2022_35_Article_IEq528.gif

41116_2022_35_Article_IEq522.gif

Fig. 31

41116_2022_35_Article_IEq517.gif

Fig. 29

41116_2022_35_Article_IEq492.gif